Intermittent versus continuous androgen suppression for prostatic cancer.

  title={Intermittent versus continuous androgen suppression for prostatic cancer.},
  author={Pio Conti and Alvaro Nagib Atallah and Horacio Arruda and Bernardo G O Soares and Regina El Dib and Timothy J. Wilt},
  journal={The Cochrane database of systematic reviews},
BACKGROUND After lung cancer, prostate cancer is the most common cause of death among males. The aim of treatment is to prevent disease-related morbidity and mortality while minimizing intervention-related adverse events. Androgen suppression therapy (AST) to reduce circulating serum testosterone and disease progression is considered a mainstay of treatment for men with advanced prostate cancer. It has been increasingly utilized for early stage disease despite a lack of evidence of… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 23 extracted citations

Prostate cancer: ESMO Consensus Conference Guidelines 2012.

Annals of oncology : official journal of the European Society for Medical Oncology • 2013
View 20 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…